A detailed history of Ubs Group Ag transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Ubs Group Ag holds 84,733 shares of VRDN stock, worth $1.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
84,733
Previous 230,376 63.22%
Holding current value
$1.68 Million
Previous $3 Million 35.7%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.16 - $23.33 $1.77 Million - $3.4 Million
-145,643 Reduced 63.22%
84,733 $1.93 Million
Q2 2024

Aug 13, 2024

SELL
$11.6 - $17.26 $1.73 Million - $2.58 Million
-149,208 Reduced 39.31%
230,376 $3 Million
Q1 2024

May 13, 2024

BUY
$17.09 - $23.82 $4.04 Million - $5.63 Million
236,198 Added 164.73%
379,584 $6.65 Million
Q4 2023

Feb 09, 2024

BUY
$11.12 - $22.5 $833,666 - $1.69 Million
74,970 Added 109.58%
143,386 $3.12 Million
Q3 2023

Nov 09, 2023

SELL
$15.16 - $24.7 $169,261 - $275,775
-11,165 Reduced 14.03%
68,416 $1.05 Million
Q2 2023

Aug 11, 2023

BUY
$22.57 - $29.67 $243,530 - $320,139
10,790 Added 15.69%
79,581 $1.89 Million
Q1 2023

May 12, 2023

SELL
$25.04 - $37.6 $1.93 Million - $2.89 Million
-76,987 Reduced 52.81%
68,791 $1.75 Million
Q4 2022

Feb 08, 2023

BUY
$18.78 - $29.74 $1.81 Million - $2.87 Million
96,481 Added 195.71%
145,778 $4.26 Million
Q3 2022

Nov 10, 2022

BUY
$10.7 - $25.5 $527,338 - $1.26 Million
49,284 Added 379107.69%
49,297 $1.01 Million
Q2 2022

Aug 10, 2022

SELL
$9.55 - $19.0 $1,995 - $3,971
-209 Reduced 94.14%
13 $0
Q1 2022

May 16, 2022

BUY
$16.79 - $20.88 $3,509 - $4,363
209 Added 1607.69%
222 $4,000
Q4 2021

Feb 14, 2022

SELL
$15.65 - $21.5 $22,379 - $30,745
-1,430 Reduced 99.1%
13 $0
Q3 2021

Nov 15, 2021

BUY
$10.69 - $18.2 $15,286 - $26,026
1,430 Added 11000.0%
1,443 $24,000
Q1 2021

May 12, 2021

BUY
$15.5 - $24.93 $201 - $324
13 New
13 $0

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $789M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.